Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22495305 | 0.79 | DRD2 (0.65) | LMNAL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL13273160 | 0.78 | LMNA (0.57) | LMNAALDH1A1MAPTSMN1; SMN2TP53 | |
| SCHEMBL29499599 | 0.78 | GRIN2D (0.59) | LMNAALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL19998348 | 0.78 | GRIN2D (0.59) | LMNAALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2490601 | 0.78 | KMT2A (0.53) | LMNAL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL8931660 | 0.78 | MAPT (0.69) | LMNAL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL9203972 | 0.78 | KMT2A (0.70) | LMNAL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL10834319 | 0.78 | HTR3A (0.62) | LMNAL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL21261259 | 0.76 | DRD2 (0.69) | LMNAALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL2744824 | 0.75 | OPRM1 (0.43) | LMNAL3MBTL1ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | claimed |
| WO-2010077861-A1 | INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-07-08 | — | — | WO | claimed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | claimed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2378878-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010077861-A1 | INHIBITORS OF DIACYLGLYCEROL ACLYTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-17 | — | — | US | disclosed |
| US-5650411-A | BACTERICIDES FOR HELICOBACTER DISEASES AND BACTERIA RESISTANCE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-22 | — | — | US | disclosed |
| CN-1118138-A | Substituted azolone derivatives for treating diseases caused by helicobacter | JANSSEN PHARMACEUTICA NV (BE) | 1996-03-06 | — | — | CN | disclosed |
| EP-0684821-A1 | SUBSTITUTED AZOLONE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018978-A1 | SUBSTITUTED AZOLONE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152445-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT2, DGAT1, ACAT2 | LMNA 4374/4885L3MBTL1 1674/4885ALDH1A1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.